IL6 and temporal arteritis: Baricitinib, tofacitinib, and upadacitinib have been demonstrated to suppress vascular inflammation in murine models and to achieve clinical remission in approximately 60% of patients with relapsing GCA in real-world settings, including those refractory to IL-6 blockade [102].